KT-294

KT-294 is a first-in-class, highly selective, orally bioavailable small molecule degrader of tyrosine-protein kinase 2 (TYK2), developed by Kymera Therapeutics. It is designed to achieve deep and sustained degradation of TYK2 in vivo with low oral doses. By targeting both the catalytic and scaffolding functions of TYK2, KT-294 recapitulates the biology seen in human TYK2 loss-of-function mutations—potently inhibiting IL-12, IL-23, and Type I interferon (IFN) pathways while sparing IL-10/IL-22 signaling. This selectivity differentiates it from other TYK2 inhibitors such as deucravacitinib (which also inhibits JAK1 and suppresses IL-10) and TAK-279 (which does not fully inhibit Type I IFN). The drug’s mechanism offers potential advantages for treating immune-inflammatory diseases like inflammatory bowel disease, psoriasis, psoriatic arthritis, lupus, and interferonopathies[1][3][5][6][8].

Other names

KT 294KT294KT-294